Profile data is unavailable for this security.
About the company
Edgewise Therapeutics, Inc. is a clinical-stage biopharmaceutical company. It is focused on developing novel therapeutics for muscular dystrophies and serious cardiac conditions. It has built its muscle-focused drug discovery platform. Its platform utilizes custom-built high throughput and translatable systems that measure integrated muscle function in whole organ extracts to identify small molecule precision medicines regulating key proteins in muscle tissue, initially focused on addressing rare neuromuscular and cardiac diseases. Its lead product candidate, EDG-5506, is an orally administered allosteric, selective, fast myofiber (type II) myosin small molecule inhibitor designed to address the root cause of dystrophinopathies, including Duchenne muscular dystrophy and Becker muscular dystrophy. Its product candidate, EDG-7500, for the treatment of hypertrophic cardiomyopathy addition to exploring the potential of its mechanism in the treatment of disorders of diastolic dysfunction.
- Revenue in USD (TTM)0.00
- Net income in USD-124.29m
- Incorporated2017
- Employees108.00
- LocationEdgewise Therapeutics Inc1715 38Th StBOULDER 80301United StatesUSA
- Phone+1 (720) 262-7002
- Fax+1 (302) 636-5454
- Websitehttps://edgewisetx.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Veracyte Inc | 425.33m | -9.27m | 2.94bn | 815.00 | -- | 2.52 | 205.78 | 6.91 | -0.1445 | -0.1445 | 5.61 | 15.18 | 0.3545 | 7.40 | 9.66 | 521,878.50 | -0.7723 | -6.33 | -0.8157 | -6.69 | 68.45 | 67.10 | -2.18 | -20.99 | 4.79 | -- | 0.00009 | -- | 21.76 | 31.45 | -103.51 | -- | 39.67 | -- |
| Iovance Biotherapeutics Inc | 90.86m | -410.00m | 2.94bn | 557.00 | -- | 3.82 | -- | 32.37 | -1.50 | -1.50 | 0.3273 | 2.54 | 0.0986 | 3.24 | -- | 163,120.30 | -44.48 | -51.47 | -50.17 | -57.56 | 14.75 | -- | -451.25 | -137,873.80 | 3.90 | -- | 0.0013 | -- | -- | -- | -12.16 | -- | 79.44 | -- |
| Dyne Therapeutics Inc | 0.00 | -257.60m | 2.94bn | 152.00 | -- | 3.79 | -- | -- | -3.58 | -3.58 | 0.00 | 7.74 | 0.00 | -- | -- | 0.00 | -47.82 | -52.81 | -50.15 | -57.45 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -40.36 | -- | 40.32 | -- |
| ACADIA Pharmaceuticals Inc | 929.24m | 128.51m | 2.98bn | 620.00 | 23.13 | 5.17 | 21.19 | 3.21 | 0.7753 | 0.7753 | 5.60 | 3.47 | 1.15 | 1.91 | 9.73 | 1,556,509.00 | 15.97 | -27.50 | 24.34 | -32.73 | 91.61 | 95.62 | 13.83 | -38.35 | 2.11 | -- | 0.00 | -- | 40.45 | 26.55 | 71.62 | -- | 79.52 | -- |
| Vera Therapeutics Inc | 0.00 | -134.38m | 3.01bn | 82.00 | -- | 9.24 | -- | -- | -2.60 | -2.60 | 0.00 | 5.25 | 0.00 | -- | -- | 0.00 | -49.39 | -- | -54.50 | -- | -- | -- | -- | -- | -- | -- | 0.1487 | -- | -- | -- | -7.79 | -- | -- | -- |
| Amicus Therapeutics, Inc. | 493.67m | -104.69m | 3.13bn | 517.00 | -- | 17.52 | -- | 6.35 | -0.3461 | -0.3461 | 1.63 | 0.5987 | 0.6367 | 0.5739 | 5.76 | 954,876.20 | -13.50 | -30.65 | -17.12 | -36.55 | 89.99 | 88.94 | -21.21 | -86.10 | 2.42 | 0.3214 | 0.6853 | -- | 21.30 | 34.35 | 35.92 | -- | 3.36 | -- |
| Kymera Therapeutics Inc | 87.56m | -167.47m | 3.24bn | 184.00 | -- | 3.63 | -- | 36.98 | -2.33 | -2.33 | 1.26 | 13.79 | 0.1103 | -- | 34.37 | 468,251.30 | -21.10 | -23.03 | -22.98 | -27.64 | -- | -- | -191.26 | -207.82 | -- | -- | 0.0035 | -- | 67.84 | -- | 5.07 | -- | 91.01 | -- |
| Xenon Pharmaceuticals Inc | 0.00 | -199.06m | 3.29bn | 251.00 | -- | 3.89 | -- | -- | -2.74 | -2.74 | 0.00 | 11.15 | 0.00 | -- | -- | 0.00 | -25.38 | -20.71 | -26.37 | -21.81 | -- | -- | -- | -683.58 | -- | -- | 0.00 | -- | -100.00 | -- | -45.99 | -- | 61.77 | -- |
| Edgewise Therapeutics Inc | 0.00 | -124.29m | 3.30bn | 108.00 | -- | 6.80 | -- | -- | -1.49 | -1.49 | 0.00 | 5.18 | 0.00 | -- | -- | 0.00 | -30.22 | -- | -31.57 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -48.08 | -- | -- | -- |
| MoonLake Immunotherapeutics | 0.00 | -80.77m | 3.32bn | 50.00 | -- | 6.70 | -- | -- | -1.29 | -1.29 | 0.00 | 7.74 | 0.00 | -- | -- | 0.00 | -16.25 | -- | -18.06 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | 27.95 | -- | -- | -- |
| Apogee Therapeutics Inc | 0.00 | -118.49m | 3.35bn | 91.00 | -- | 4.20 | -- | -- | -2.25 | -2.25 | 0.00 | 13.65 | 0.00 | -- | -- | 0.00 | -25.44 | -- | -26.65 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -111.10 | -- | -- | -- |
| Agios Pharmaceuticals Inc | 32.87m | 727.43m | 3.37bn | 383.00 | 4.81 | 2.07 | 4.59 | 102.40 | 12.28 | 11.37 | 0.5778 | 28.53 | 0.0235 | 0.1598 | 15.31 | 85,825.06 | 51.98 | -29.54 | 55.50 | -31.88 | 89.38 | -- | 2,212.98 | -3,826.10 | 8.77 | -- | 0.00 | -- | 88.36 | -22.25 | -51.89 | -- | -32.23 | -- |
| Immunitybio Inc | 1.31m | -597.65m | 3.45bn | 622.00 | -- | -- | -- | 2,635.96 | -0.9356 | -0.9356 | 0.0021 | -1.01 | 0.0036 | -- | 0.49 | 2,082.80 | -162.54 | -112.76 | -1,927.61 | -316.07 | -- | -- | -45,701.07 | -37,700.74 | 3.88 | -2.33 | 3.69 | -- | 159.17 | 67.62 | -40.00 | -- | 18.48 | -- |
Data as of Nov 13 2024. Currency figures normalised to Edgewise Therapeutics Inc's reporting currency: US Dollar USD
43.56%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| RA Capital Management LPas of 30 Jun 2024 | 8.91m | 9.50% |
| Baker Bros. Advisors LPas of 30 Jun 2024 | 5.84m | 6.23% |
| BlackRock Fund Advisorsas of 30 Jun 2024 | 5.39m | 5.75% |
| The Vanguard Group, Inc.as of 30 Jun 2024 | 4.33m | 4.62% |
| Fidelity Management & Research Co. LLCas of 30 Jun 2024 | 4.25m | 4.53% |
| Cormorant Asset Management LPas of 30 Jun 2024 | 3.01m | 3.21% |
| Janus Henderson Investors US LLCas of 30 Jun 2024 | 2.59m | 2.76% |
| Citadel Advisors LLCas of 30 Jun 2024 | 2.35m | 2.51% |
| Paradigm BioCapital Advisors LPas of 30 Jun 2024 | 2.33m | 2.48% |
| Perceptive Advisors LLCas of 30 Jun 2024 | 1.86m | 1.98% |
More ▼
Data from 30 Jun 2024 - 30 Jun 2024Source: FactSet Research Systems Inc.
